0 item $0.00

Professor Judy de Haan

Professor Judy de Haan

Head: Cardiovascular Inflammation and Redox Biology


La Trobe University supervisor

Monash University supervisor

Swinburne University supervisor

Torrens University supervisor

University of Melbourne

Laboratory Head

+61 3 8532 1520

Professor Judy de Haan is a Baker Institute Fellow and Head of the Cardiovascular Inflammation and Redox Biology laboratory at the Baker Heart and Diabetes Institute. She holds adjunct Professorships through Swinburne and La Trobe University and an Associate Professorship appointment through Torrens University, Adelaide, with senior lectureships in the Departments of Immunology and Diabetes, at Monash University and is an Honorary Principal Fellow at Melbourne University. She is an elected member of the Australian Cardiovascular Alliance: Drug Discovery Flagship (2019-), a past Director of the Australian Atherosclerosis Society (2021–2022) and the President of the Australian Atherosclerosis Society (2023–2025).

Prof de Haan’s research focuses on improving the lives of diabetic patients by reducing the burden of cardiovascular complications. A focus has been on the pathogenesis of oxidant stress, where free radicals build up in the body and elicit damage, in particular, their contribution to diabetic macrovascular complications, such as diabetes-associated atherosclerosis and diabetes-linked endothelial dysfunction. This has led to significant discoveries on the role of endogenous antioxidant enzyme defences to limit disease. Her work has identified several key antioxidant enzyme mimetics, as well as activators of the transcriptional regulator of oxidant stress, Nrf2, as novel therapeutic strategies to lessen diabetic cardiovascular complications. Her research now focuses on the interplay between antioxidant defence and inflammation, with a particular focus on the Nrf2/NLRP3-inflammasome axis. Her preclinical investigations hold tremendous potential for translation into humans, and this next phase of her research is anticipated to yield far better cardiovascular outcomes than previous non-selective antioxidants such as vitamins C and E.

In addition, a recent approach, together with the University of Swinburne, has been the development of an interdisciplinary molecular, cell biology and surface engineering strategy to limit regrowth and obstruction of heart vessels after stent surgery.

Professor de Haan has more than 90 career publications with more than 5500 career citations, and an H-index of 43, many published in highly ranked scientific journals such as Circulation, Diabetes, Human Mol Genet, ATVB, Kidney Int and JBC.

Professor de Haan's work has been supported by grants from the NHMRC, National Heart Foundation, Diabetes Australia Research Program, the Victorian Government, as well as numerous industry awards.


  • Australian Atherosclerosis Society (AAS) committee President (2023–)
  • Australian Atherosclerosis Society (AAS) committee Director (2020–2022)
  • Founding member, Baker Institute Gender Equity and Diversity Committee (2014–)
  • Member of the Drug Discovery and Translation Flagship of the Australian Cardiovascular Alliance (2019–)
  • Australian Atherosclerosis Society (AAS) committee member (2010–2013)
  • Editorial Board Member of Frontiers in Integrative Physiology, Antioxidants and Reactive Oxygen Species, and Journal Lipid Atherosclerosis

Publication highlights

Support us

With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.

Find out more